WebSep 15, 2024 · What Is Bivalirudin? Bivalirudin (bivalirudin injection, powder, lyophilized, for solution) is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein … WebThe most recently published HEAT-PPCI trial recruited STEMI patients undergoing primary PCI randomized to receive either bivalirudin or heparin, with the use of Gp IIb/IIIa inhibitors restricted to bailout in both groups. 57 It was the first major trial making a head-to-head comparison between bivalirudin and heparin with a nondifferential Gp ...
Effectiveness and safety of bivalirudin in elderly patients with ...
WebHeparin has been used in the catheterization laboratory to prevent ischemic complications of percutaneous coronary intervention (PCI). Bivalirudin, a direct thrombin inhibitor, is an anticoagulant that has several pharmacologic advantages over heparin, and it has been proposed that bivalirudin is superior to heparin in its ability to prevent bleeding … WebPost-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease the rate of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (11.0% and 11.9%, respectively; relative risk, 0.91; 95% CI, 0.74 to 1.11; P = 0.34). CONCLUSIONS In patients with an acute coronary syndrome ... brighthouse annuities contact
DailyMed - ANGIOMAX- bivalirudin injection
WebJan 30, 2024 · The ideal parenteral antiplatelet agent would provide immediate and robust periprocedural ischemic benefit without attendant excess bleeding risk. 3 GPIIb/IIIa inhibitors have been associated with reduced thrombotic events after PCI compared with heparin and bivalirudin therapy alone, 3-5,35,49 but their routine use, notably with prolonged ... WebNov 8, 2024 · The largest randomized trial directly comparing bivalirudin with a high-dose infusion for two to four hours after treatment against unfractionated heparin without the … WebJul 18, 2014 · Switching to bivalirudin before primary PCI resulted in significantly reduced 30-day and 2-year major bleeding (Figure 1). (4) Consistent with the overall trial, the switching strategy also yielded significant reductions in cardiac mortality and reinfarction. These results were not related to the pre-procedure activated clotting time (ACT) value. brighthouse annuity appointment